{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T09:33:10Z","timestamp":1773739990313,"version":"3.50.1"},"reference-count":17,"publisher":"National Institute for Health and Care Research","issue":"Suppl 2","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["08\/95-01"],"award-info":[{"award-number":["08\/95-01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:p>This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia (CLL) based upon a review of the manufacturer\u2019s submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The manufacturer\u2019s searches for clinical effectiveness and cost-effectiveness data were appropriate and included all relevant studies. The submission\u2019s evidence came from a single, unpublished, well-conducted randomised controlled trial (RCT) comparing rituximab in combination with fludarabine and cyclophosphamide (R-FC) with fludarabine and cyclophosphamide (FC) alone for the first-line treatment of CLL. There was a statistically significant increase in progression-free survival (PFS) with R-FC compared with FC alone {median 39.8 months vs 32.2 months; hazard ratio [HR] 0.56 [95% confidence interval (CI) 0.43 to 0.72]}. However, the initial significant treatment benefit for R-FC compared with FC for overall survival was not maintained at a slightly longer follow-up time [median 25.4 months; adjusted HR 0.72 (95% CI 0.48 to 1.09)]. Response rates, numbers of patients with event-free survival and duration of response all favoured treatment with R-FC. Additional evidence from a mixed-treatment comparison model indicated R-FC to be significantly superior to chlorambucil alone for both PFS and overall and complete response rates. The incidence of grade 3 or 4 adverse events was higher in the R-FC arm (77%) than in the FC arm (62%). Dose modifications were also more frequent in this arm, but this did not lead to differences in treatment discontinuation. Roche used a three-state Markov model (PFS, progressed and death) to model the cost-effectiveness of R-FC compared with FC and chlorambucil alone. The model used a cycle length of 1 month and a lifetime time horizon. The approach taken to modelling was reasonable and the sources and justification of estimates were generally sound. The base-case analysis produced an incremental cost-effectiveness ratio (ICER) of \u00a313,189 per quality-adjusted life-year (QALY) for R-FC versus FC, and \u00a36422 per QALY for the comparison of R-FC versus chlorambucil, suggesting that R-FC is cost-effective at normal willingness-to-pay thresholds. One-way sensitivity analyses produced a range of ICERs from \u00a310,249 to \u00a322,661 per QALY for R-FC versus FC, and \u00a35612 and \u00a36921 per QALY for R-FC versus chlorambucil. Probabilistic sensitivity analysis results matched the deterministic results very closely. However, the sensitivity analysis did not fully investigate the uncertainty associated with differential values across arms or with the structural assumptions of the model, and utility values were not drawn from an empirical study. The NICE guidance issued as a result of the STA states that: Rituximab in combination with fludarabine and cyclophosphamide (R-FC) is recommended as an option for the first-line treatment of chronic lymphocytic leukaemia in people for whom fludarabine in combination with cyclophosphamide (FC) is considered appropriate. \u2009Rituximab in combination with chemotherapy agents other than fludarabine and cyclophosphamide is not recommended for the first-line treatment of chronic lymphocytic leukaemia.<\/jats:p>","DOI":"10.3310\/hta14suppl2-04","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T18:12:28Z","timestamp":1613067148000},"page":"27-32","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche"],"prefix":"10.3310","volume":"14","author":[{"given":"C","family":"Main","sequence":"first","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), Exeter, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Pitt","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), Exeter, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Moxham","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), Exeter, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Stein","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), Exeter, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6221","published-online":{"date-parts":[[2010,10]]},"reference":[{"key":"key20210211165049781_ref1-bib1","volume-title":"Guide to the single technology (STA) process","author":"National Institute for Health and Clinical Excellence","year":"2006"},{"key":"key20210211165049781_ref1-bib2","volume-title":"The clinical and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche","author":"Main","year":"2009"},{"key":"key20210211165049781_ref1-bib3","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/sj.leu.2403154","article-title":"Unsolved issues in CLL biology and management","volume":"17","author":"Dighiero","year":"2003","journal-title":"Leukemia"},{"key":"key20210211165049781_ref1-bib4","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"key20210211165049781_ref1-bib5","unstructured":"Roche. CLL8 final clinical study report ML17102. 2008."},{"key":"key20210211165049781_ref1-bib6","volume-title":"Fludarabine as first-line therapy for chronic lymphocytic leukaemia","author":"Hancock","year":"2002"},{"key":"key20210211165049781_ref1-bib7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"key20210211165049781_ref1-bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/cbr.1997.12.177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs","volume":"12","author":"Demidem","year":"1997","journal-title":"Cancer Biother Radiopharm"},{"key":"key20210211165049781_ref1-bib9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1042\/bst0250705","article-title":"Targeting cytotoxic immunotherapy","volume":"25","author":"Anderson","year":"1997","journal-title":"Biochem Soc Trans"},{"key":"key20210211165049781_ref1-bib10","unstructured":"NHS Centre for Reviews and Dissemination. Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care. Report No. 4 update. York: CRD, University of York; 2009."},{"key":"key20210211165049781_ref1-bib11","volume-title":"Guide to the methods of technology appraisal","author":"National Institute for Health and Clinical Excellence","year":"2008"},{"key":"key20210211165049781_ref1-bib12","volume-title":"Methods for the economic evaluation of health care programmes 47","author":"Drummond","year":"1997"},{"key":"key20210211165049781_ref1-bib13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00019053-200624040-00006","article-title":"Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment","volume":"24","author":"Philips","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"key20210211165049781_ref1-bib14","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"key20210211165049781_ref1-bib15","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"key":"key20210211165049781_ref1-bib16","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20210211165049781_ref1-bib17","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2035673","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta14suppl2-04\/hta14suppl2-04.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2035673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:37:30Z","timestamp":1692113850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta14suppl2-04"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":17,"aliases":["10.3310\/hta14suppl2\/04"],"journal-issue":{"issue":"Suppl 2","published-online":{"date-parts":[[2010,10]]}},"alternative-id":["10.3310\/hta14suppl2-04"],"URL":"https:\/\/doi.org\/10.3310\/hta14suppl2-04","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"1-2009","name":"date_of_ERG_submission","label":"Date of ERG submission","group":{"name":"article_history","label":"Article History"}},{"value":"4-2009","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"5-2009","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}